Equity Overview
Price & Market Data
Price: $12.86
Daily Change: $0.00 / 0.00%
Range: $0 - $0
Market Cap: $0
Volume: 0
Performance Metrics
1 Week: 10.20%
1 Month: -79.09%
3 Months: -79.13%
6 Months: -79.13%
1 Year: -79.13%
YTD: -79.13%
Details
Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark and the United States. The company has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. It also provides Zegalogue, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing insulin and dasiglucagon. Its pipeline includes Dasiglucagon for treating congenital hyperinsulinism. In addition, the company developing glepaglutide, a long acting GLP-2 analog, which is in Phase III clinical trials for the treatment of short bowel syndrome. Zealand Pharma A/S was incorporated in 1997 and is based in Søborg, Denmark.